These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12913980)

  • 1. [The use of moxonidine in patients with essential hypertension combined with metabolic syndrome].
    Syrtlanova ER; Gil'mutdinova LT
    Kardiologiia; 2003; 43(3):33-5. PubMed ID: 12913980
    [No Abstract]   [Full Text] [Related]  

  • 2. Moxonidine suitable for hypertensive menopausal women with metabolic syndrome.
    Cardiovasc J S Afr; 2005; 16(3):186. PubMed ID: 16049602
    [No Abstract]   [Full Text] [Related]  

  • 3. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A; Lithell H
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Optimizing antihypertensive therapy].
    Schlimpert V
    MMW Fortschr Med; 2015 Feb; 157(3):66. PubMed ID: 25743673
    [No Abstract]   [Full Text] [Related]  

  • 10. Alpha Blockers and Metabolic Syndrome.
    Kabra NK
    J Assoc Physicians India; 2014 Sep; 62(9 Suppl):13-6. PubMed ID: 26245037
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
    Masajtis-Zagajewska A; Majer J; Nowicki M
    Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome].
    Vengerovskiĭ AI; Idrisova EM; Bushkova EA; Mananko EI; Krasnova NM
    Eksp Klin Farmakol; 2008; 71(6):8-12. PubMed ID: 19140507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare psychotropic adverse event of moxonidine.
    Fuckar K; Lakusić N; Cerovec D
    Psychiatr Danub; 2009 Dec; 21(4):518. PubMed ID: 19935487
    [No Abstract]   [Full Text] [Related]  

  • 14. [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)].
    Krupicka J; Soucek M; Chroust K
    Vnitr Lek; 2011 Jun; 57(6):541-5. PubMed ID: 21751539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A
    Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
    Kseneva SI; Borodulina EV; Semiglazova TA; Kulakova NV; Tarasova IV; Trifonova OJ; Gridneva TD; Udut VV
    Bull Exp Biol Med; 2011 Aug; 151(4):400-4. PubMed ID: 22448351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
    Ebinç H; Ozkurt ZN; Ebinç FA; Ucardag D; Caglayan O; Yilmaz M
    J Int Med Res; 2008; 36(1):80-7. PubMed ID: 18230271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of lisinopril on platelet aggregation in patients with arterial hypertension with metabolic syndrome].
    Medvedev IN; Gromnatskiĭ NI; Golikov BM; Al'-Zuraĭki EM; Li VIu
    Kardiologiia; 2004; 44(10):57-9. PubMed ID: 15477792
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical assessment of prolonged therapy of patients with hypertension and diabetes with imidazoline receptor agonist moxonidine].
    Trusov VV; Aksenov KV; Filimonov MA
    Kardiologiia; 2002; 42(2):50-3. PubMed ID: 12494208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.